Based on the ImmuCell Corporation stock forecast from 0 analysts, the average analyst target price for ImmuCell Corporation is not available over the next 12 months. ImmuCell Corporation’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of ImmuCell Corporation is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, ImmuCell Corporation’s stock price was USD 5.38. ImmuCell Corporation’s stock price has changed by +12.32% over the past week, +5.32% over the past month and +3.07% over the last year.
Past 12 monthsNext 12 months
No recent analyst target price found for ImmuCell Corporation
No recent average analyst rating found for ImmuCell Corporation
Company Overview ImmuCell Corporation
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E. coli, coronavirus, and rotavirus; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test, a quick on-farm diagnostic that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, a bivalent gel tube formulation. In addition, it is developing Re-Tain Drug Product, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine. Read Less
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First D...Read More
Frequently Asked Questions About ImmuCell Corporation (ICCC) Stock
Stock Target Advisor's fundamental analysis for ImmuCell Corporation's stock is Bearish.
Unfortunately we do not have enough data on ICCC's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ICCC's stock to indicate what its average analyst target is.
ICCC stock's Price/Earning ratio is 170.25.
Our analysis grades ICCC stock's Price / Earning ratio at F. This means that ICCC stock's Price/Earning ratio is above 93% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ICCC may be a overvalued for its sector.
The last closing price of ICCC's stock was USD 5.38.
The most recent market capitalization for ICCC is USD 0.03B.
Unfortunately we do not have enough analyst data on ICCC's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ImmuCell Corporation's stock.
As per our most recent records ImmuCell Corporation has 0 Employees.
ImmuCell Corporation's registered address is 56 Evergreen Drive, Portland, ME, United States, 04103.
You can get more information about it from ImmuCell Corporation's website at https://immucell.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About ImmuCell Corporation (ICCC) Stock
Stock Target Advisor's fundamental analysis for ImmuCell Corporation's stock is Bearish.
Unfortunately we do not have enough data on ICCC's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ICCC's stock to indicate what its average analyst target is.
ICCC stock's Price/Earning ratio is 170.25.
Our analysis grades ICCC stock's Price / Earning ratio at F. This means that ICCC stock's Price/Earning ratio is above 93% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ICCC may be a overvalued for its sector.
The last closing price of ICCC's stock was USD 5.38.
The most recent market capitalization for ICCC is USD 0.03B.
Unfortunately we do not have enough analyst data on ICCC's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains ImmuCell Corporation's stock.
As per our most recent records ImmuCell Corporation has 0 Employees.
ImmuCell Corporation's registered address is 56 Evergreen Drive, Portland, ME, United States, 04103.
You can get more information about it from ImmuCell Corporation's website at https://immucell.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ICCC !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
